Yesterday we published the first half of our comprehensive behind-the-scenes interview with Joslin Diabetes Center CEO John Brooks III — who by the way took part in the 2012 DiabetesMine Innovation Summit.
Today, we continue talking with John, learning more about the legendary center, and digging into all the current ‘hot buttons’ in diabetes innovation and care:
DM) How much of Joslin’s focus is pure research?
JB) About 40% of our total focus is…
Read more »
JOSLIN… Just the sound of it makes the heart of most PWDs (people with diabetes) skip a beat. It stands for the world’s leading center for diabetes research, clinical care and education based in Boston, MA. It also harkens back to its namesake founder, Dr. Elliott Joslin, regarded as the father of modern diabetes care.
Ever wonder who currently heads up this amazing place? And what exactly they are doing to bring this Century-old institution…
Read more »
As a follow up to the 2012 DiabetesMine Innovation Summit event held last November at Stanford University, we wanted to share the gist of the keynote talk about why the development of standards for diabetes devices and data is so crucial.
We had thought to create a white paper on the topic, but on the recommendation of the wonderful Kelly Close of Close Concerns, decided that a video version would be much more impactful; it’s…
Read more »
By
MikeH on
February 5, 2013
Many in the Diabetes Community are anxiously awaiting the release of the smaller and sleeker 2nd generation OmniPod, but already we know what a third generation won’t have:
A Pod that’s integrated with a Dexcom CGM sensor.
Yep, it’s true: the two companies say they have abandoned the integration deal they had in place since 2008.
Two executives at Massachusetts-based Insulet Corp., makers of the OmniPod, say they’re no longer working with California-based Dexcom on…
Read more »
By
AmyT on
January 31, 2013
The fact is, a handful of manufacturers currently have a stronghold on our diabetes data. Their systems collect this vital health data for us, but are designed to withhold it so that we rely on their products exclusively to access it, share it, or analyze it.
More and more patients are finding this intolerable, and are fed up with waiting for the Pharma industry to embrace long-overdue open standards.
I’m a bit obsessed with this…
Read more »
